CYTK

Several events have impacted Cytokinetics' stock price in the past six months. The FDA approval of MYQORZO in December 2025, just outside the six-month window, established a positive trajectory. In Q1 2026, strong U.S. launch demand for MYQORZO was reported, the ACACIA-HCM trial met its dual primary endpoints, and MYQORZO received European Commission approval, contributing to a stock rally. Q2 2026 saw MYQORZO net product revenue surpass forecasts, and the company announced plans to submit a supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026, alongside continued international launches. Cytokinetics filed a patent lawsuit against Bristol-Myers Squibb in August 2026 to prevent potential patent infringement claims related to MYQORZO, with analysts believing Cytokinetics likely has the 'upper hand'. Reports of insider selling by the CEO and other executives in August-September 2026, including a large block under a pre-arranged trading plan, were noted. Wholesale sales of MYQORZO were reportedly tracking to double in Q3 2026 compared to Q2 2026, indicating continued strong commercial performance.